US FDA asks stakeholders how they are addressing bias, reproducibility and data privacy in application of AI/ML. Discussion paper describes current and potential uses of artificial intelligence and machine learning in drug development.
The US Food and Drug Administration laid out the challenges that need to be addressed in using artificial intelligence and machine learning in drug development, from transparency to the quality, reliability and representativeness of data and monitoring and validation of AL/ML models.
In a discussion paper, entitled "Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products,"...
States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.
The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.
Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.
